TABLE OF CONTENTS
1 INTRODUCTION 52
1.1 OBJECTIVES OF THE STUDY 52
1.2 MARKET DEFINITION 52
1.3 OVERVIEW OF THE ASIA-PACIFIC VENOUS DISEASES TREATMENT MARKET 52
1.4 CURRENCY AND PRICING 54
1.5 LIMITATIONS 55
1.6 MARKETS COVERED 55
2 MARKET SEGMENTATION 60
2.1 MARKETS COVERED 60
2.2 GEOGRAPHICAL SCOPE 61
2.3 YEARS CONSIDERED FOR THE STUDY 62
2.4 DBMR TRIPOD DATA VALIDATION MODEL 63
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 66
2.6 MULTIVARIATE MODELLING 67
2.7 MARKET END USER COVERAGE GRID 68
2.8 INSTRUMENT BASED LIFELINE CURVE 69
2.9 DBMR MARKET POSITION GRID 70
2.10 VENDOR SHARE ANALYSIS 72
2.11 SECONDARY SOURCES 73
2.12 ASSUMPTIONS 73
3 EXECUTIVE SUMMARY 74
4 PREMIUM INSIGHTS 77
4.1 PESTEL ANALYSIS 78
4.2 PORTER'S FIVE FORCES 79
5 ASIA-PACIFIC VENOUS DISEASES TREATMENT MARKET, INDUSTRY INSIGHTS 80
6 EPIDEMIOLOGY 82
7 REGULATORY FRAMEWORK 83
8 MARKET OVERVIEW 86
8.1 DRIVERS 88
8.1.1 RISING INCIDENCES OF VENOUS DISEASES 88
8.1.2 RAPID CHANGES IN LIFESTYLE LEAD TO OBESITY RESULTING IN VENOUS DISEASES 88
8.1.3 INCREASE IN THE GERIATRIC POPULATION 89
8.1.4 TECHNOLOGICALLY ADVANCEMENT IN THE TREATMENT OF VENOUS DISEASES 90
8.2 RESTRAINTS 91
8.2.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 91
8.2.2 INADEQUATE REIMBURSEMENT COVERAGE 91
8.3 OPPORTUNITIES 92
8.3.1 RISING AWARENESS TOWARDS VENOUS DISORDERS 92
8.3.2 NEED FOR PROPER DIAGNOSIS AND TREATMENT OF VENOUS DISEASES 92
8.3.3 GROWING PREFERENCE FOR MINIMALLY INVASIVE PROCEDURES 93
8.3.4 OCCUPATIONAL LIFESTYLE INCREASES THE NEED FOR VENOUS DISEASE TREATMENT 93
8.4 CHALLENGES 94
8.4.1 HIGH COST ASSOCIATED WITH VENOUS DISEASE TREATMENT 94
8.4.2 SIDE EFFECTS AND RISK ASSOCIATED WITH DIFFERENT TREATMENT MODES 95
9 ASIA-PACIFIC VENOUS DISEASES TREATMENT MARKET, BY PRODUCT TYPE 96
9.1 OVERVIEW 97
9.2 SCLEROTHERAPY INJECTION 100
9.2.1 SCLEROTHERAPY, BY TYPE 100
9.2.1.1 INTRAVENOUS 101
9.2.1.2 INTRADERMAL 101
9.2.1.3 SUBCUTANEOUS 101
9.2.2 SUBCUTANEOUS, BY APPLICATION 101
9.2.2.1 MALFORMED LYMPHED VESSELS 101
9.2.2.2 HEMORRHOIDS 101
9.2.2.3 HYDROCELES 101
9.2.2.4 OTHERS 101
9.3 ABLATION DEVICES 101
9.3.1 THERMAL ABLATION 102
9.3.1.1 RADIOFREQUENCY 103
9.3.1.1.1 CATHETER MANIPULATION SYSTEMS 103
9.3.1.1.2 TEMPERATURE CONTROLLED 103
9.3.1.1.3 FLUID COOLED 104
9.3.1.2 LIGHT 104
9.3.1.2.1 EXCIMER LASERS 104
9.3.1.2.2 COLD LASERS 104
9.3.1.3 ULTRASOUND 104
9.3.1.3.1 HIGH INTENSITY FOCUSED ULTRASOUND (HIFU) 105
9.3.1.3.2 SHOCK WAVE LITHOTRIPSY 105
9.3.1.3.3 MAGNETIC RESONANCE IMAGING GUIDED FOCUSED ULTRASOUND (MRI-FUS) 105
9.3.1.3.4 ULTRASONIC SURGICAL SYSTEMS 105
9.3.1.4 RADIATION 105
9.3.1.4.1 STEREOTACTIC BODY RADIATION THERAPY 106
9.3.1.4.2 INTENSITY-MODULATED RADIATION THERAPY 106
9.3.1.4.3 STEREOTACTIC RADIOTHERAPY & RADIOSURGERY 106
9.3.1.4.4 IMAGE GUIDED RADIATION THERAPY 106
9.3.1.4.5 INTRAVASCULAR BRACHYTHERAPY 106
9.3.1.4.6 PROTON BEAM THERAPY 106
9.3.1.5 ELECTRICAL 106
9.3.1.5.1 ELECTRICAL ABLATORS 107
9.3.1.5.2 ELECTRONIC BRACHYTHERAPY 107
9.3.1.6 MICROWAVE 107
9.3.1.7 HYDROTHERMAL 107
9.3.2 NON-THERMAL ABLATION 107
9.3.2.1 CRYOABLATION 107
9.3.2.1.1 EPIDERMAL AND SUBCUTANEOUS CRYOABLATION DEVICES 108
9.3.2.1.2 CRYOGEN SPRAY PROBE 108
9.3.2.1.3 TISSUE CONTACT PROBE 108
9.3.2.2 HYDROMECHANICAL ABLATION 108
9.4 VENOUS CLOSURE PRODUCTS 108
9.4.1 VENOUS CLOSURE PRODUCTS, BY PROCEDURE 109
9.4.1.1 INTERVENTIONAL CARDIOLOGY 109
9.4.1.2 INTERVENTIONAL RADIOLOGY 109
9.4.2 VENOUS CLOSURE PRODUCTS, BY TECHNOLOGY 109
9.4.2.1 FEMORAL ACCESS TECHNIQUE 110
9.4.2.2 RADIAL ACCESS TECHNIQUE 110
9.5 VENOUS STENTS 110
9.5.1 VENOUS STENTS, BY TECHNOLOGY 111
9.5.1.1 WALLSTENT TECHNOLOGY 111
9.5.1.2 ILIAC VEIN STENT TECHNOLOGY 111
9.5.2 VENOUS STENTS, BY APPLICATION 111
9.5.2.1 LEG 112
9.5.2.2 CHEST 112
9.5.2.3 ABDOMEN 112
9.5.2.4 OTHERS 112
9.6 MEDICATION 112
9.7 OTHERS 113
10 ASIA-PACIFIC VENOUS DISEASES TREATMENT MARKET, BY DISEASE TYPE 114
10.1 OVERVIEW 115
10.2 VARICOSE VEINS 118
10.3 DEEP VEIN THROMBOSIS (DVT) 118
10.4 PULMONARY EMBOLISM 119
10.5 CHRONIC VENOUS INSUFFICIENCY (CVI) 120
10.6 SUPERFICIAL THROMBOPHLEBITIS 120
10.7 OTHERS 121
11 ASIA-PACIFIC VENOUS DISEASES TREATMENT MARKET, BY TREATMENT TYPE 123
11.1 OVERVIEW 124
11.2 SCLEROTHERAPY 127
11.3 RADIOFREQUENCY ABLATION THERAPY 127
11.4 LASER TREATMENT 128
11.5 AMBULATORY PHLEBECTOMY 129
11.6 VEIN LIGATION AND STRIPPING 129
11.7 ANGIOPLASTY OR STENTING 130
11.8 SURGERIES 131
11.9 COMPRESSION THERAPY 131
11.10 VEINACTIVE MEDICATION 132
11.11 VENA CAVA FILTER 133
11.12 OTHER THERAPIES 134
12 ASIA-PACIFIC VENOUS TREATMENT DISEASES MARKET, BY END USER 135
12.1 OVERVIEW 136
12.2 HOSPITALS 139
12.3 CLINICS 139
12.4 AMBULATORY SURGICAL CENTERS 140
12.5 OTHERS 141
13 ASIA-PACIFIC VENOUS DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL 142
13.1 OVERVIEW 143
13.2 DIRECT TENDER 146
13.3 RETAIL SALES 146
13.4 OTHERS 147
14 ASIA-PACIFIC VENOUS DISEASES TREATMENT MARKET, BY REGION 148
14.1 ASIA-PACIFIC 149
14.1.1 CHINA 159
14.1.2 JAPAN 165
14.1.3 INDIA 171
14.1.4 AUSTRALIA 177
14.1.5 INDONESIA 183
14.1.6 SINGAPORE 189
14.1.7 MALAYSIA 195
14.1.8 PHILIPPINES 201
14.1.9 SOUTH KOREA 207
14.1.10 THAILAND 213
14.1.11 REST OF ASIA-PACIFIC 219
15 ASIA-PACIFIC VENOUS DISEASES TREATMENT MARKET, COMPANY LANDSCAPE 220
15.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 220
16 SWOT ANALYSIS 221
17 COMPANY PROFILE 222
17.1 MEDTRONIC 222
17.1.1 COMPANY SNAPSHOT 222
17.1.2 REVENUE ANALYSIS 222
17.1.3 COMPANY SHARE ANALYSIS 223
17.1.4 PRODUCT PORTFOLIO 223
17.1.5 RECENT DEVELOPMENTS 223
17.2 BOSTON SCIENTIFIC CORPORATION 224
17.2.1 COMPANY SNAPSHOT 224
17.2.2 REVENUE ANALYSIS 224
17.2.3 COMPANY SHARE ANALYSIS 225
17.2.4 PRODUCT PORTFOLIO 225
17.2.5 RECENT DEVELOPMENTS 226
17.3 VARIAN MEDICAL SYSTEMS, INC. 227
17.3.1 COMPANY SNAPSHOT 227
17.3.2 COMPANY SHARE ANALYSIS 227
17.3.3 PRODUCT PORTFOLIO 228
17.3.4 RECENT DEVELOPMENT 228
17.4 STRYKER 229
17.4.1 COMPANY SNAPSHOT 229
17.4.2 REVENUE ANALYSIS 229
17.4.3 COMPANY SHARE ANALYSIS 230
17.4.4 PRODUCT PORTFOLIO 230
17.4.5 RECENT DEVELOPMENT 230
17.5 KONINKLIJKE PHILIPS N.V. 231
17.5.1 COMPANY SNAPSHOT 231
17.5.2 REVENUE ANALYSIS 231
17.5.3 COMPANY SHARE ANALYSIS 232
17.5.4 PRODUCT PORTFOLIO 232
17.5.5 RECENT DEVELOPMENT 232
17.6 ABBOTT 233
17.6.1 COMPANY SNAPSHOT 233
17.6.2 REVENUE ANALYSIS 233
17.6.3 PRODUCT PORTFOLIO 234
17.6.4 RECENT DEVELOPMENT 234
17.7 ALMA LASERS 235
17.7.1 COMPANY SNAPSHOT 235
17.7.2 PRODUCT PORTFOLIO 235
17.7.3 RECENT DEVELOPMENT 235
17.8 ANGIODYNAMICS 236
17.8.1 COMPANY SNAPSHOT 236
17.8.2 REVENUE ANALYSIS 236
17.8.3 PRODUCT PORTFOLIO 237
17.8.4 RECENT DEVELOPMENT 237
17.9 B.BRAUN MELSUNGEN AG 238
17.9.1 COMPANY SNAPSHOT 238
17.9.2 REVENUE ANALYSIS 238
17.9.3 PRODUCT PORTFOLIO 239
17.9.4 RECENT DEVELOPMENTS 239
17.10 BAYLIS MEDICAL COMPANY, INC 240
17.10.1 COMPANY SNAPSHOT 240
17.10.2 PRODUCT PORTFOLIO 240
17.10.3 RECENT DEVELOPMENT 240
17.11 BD 241
17.11.1 COMPANY SNAPSHOT 241
17.11.2 REVENUE ANALYSIS 241
17.11.3 PRODUCT PORTFOLIO 242
17.11.4 RECENT DEVELOPMENT 242
17.12 CANDELA MEDICAL 243
17.12.1 COMPANY SNAPSHOT 243
17.12.2 PRODUCT PORTFOLIO 243
17.12.3 RECENT DEVELOPMENT 243
17.13 CARL ZEISS MEDITEC AG 244
17.13.1 COMPANYSNAPSHOT 244
17.13.2 REVENUE ANALYSIS 244
17.13.3 PRODUCT PORTFOLIO 245
17.13.4 RECENT DEVELOPMENT 245
17.14 COOK 246
17.14.1 COMPANY SNAPSHOT 246
17.14.2 PRODUCT PORTFOLIO 246
17.14.3 RECENT DEVELOPMENTS 246
17.15 IMRICOR 247
17.15.1 COMPANY SNAPSHOT 247
17.15.2 REVENUE ANALYSIS 247
17.15.3 PRODUCT PORTFOLIO 248
17.15.4 RECENT DEVELOPMENT 248
17.16 OLYMPUS CORPORATION 249
17.16.1 COMPANY SNAPSHOT 249
17.16.2 REVENUE ANALYSIS 249
17.16.3 PRODUCT PORTFOILIO 250
17.16.4 RECENT DEVELOPMENT 250
17.17 OPTIMED MEDIZINISCHE INSTRUMENTE GMBH 251
17.17.1 COMPANY SNAPSHOT 251
17.17.2 PRODUCT PORTFOLIO 251
17.17.3 RECENT DEVELOPMENTS 251
17.18 PLUSMEDICA.DE 252
17.18.1 COMPANY SNAPSHOT 252
17.18.2 PRODUCT PORTFOLIO 252
17.18.3 RECENT DEVELOPMENT 252
17.19 SCITECH 253
17.19.1 COMPANY SNAPSHOT 253
17.19.2 PRODUCT PORTFOLIO 253
17.19.3 RECENT DEVELOPMENTS 253
17.20 SMITH + NEPHEW 254
17.20.1 COMPANY SNAPSHOT 254
17.20.2 REVENUE ANALYSIS 254
17.20.3 PRODUCT PORTFOLIO 255
17.20.4 RECENT DEVELOPMENT 255

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.